PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

10:49 EST 15 Nov 2017 | SCRIP

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon...


Related Stories


Original Article: PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride


More From BioPortfolio on "PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...